VIRX - Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

PR Newswire

SAN DIEGO , March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston , President and Chief Executive Officer of Viracta will present at the Oppenheimer 31 ^st Annual Healthcare Conference taking place virtually from March 16-18, 2021 . Viracta's management team will also be available for one-on-one investor meetings at the conference.

Presentation details can be found below.

A replay of the presentation will be archived for 90 days on the "Events and Webcasts" section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts#past .

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application of this inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit www.viracta.com .

SOURCE Viracta